CH639244A5 - SUBSTITUTE FOOD FOR BREAST MILK AND VACCINE MILK. - Google Patents
SUBSTITUTE FOOD FOR BREAST MILK AND VACCINE MILK. Download PDFInfo
- Publication number
- CH639244A5 CH639244A5 CH332079A CH332079A CH639244A5 CH 639244 A5 CH639244 A5 CH 639244A5 CH 332079 A CH332079 A CH 332079A CH 332079 A CH332079 A CH 332079A CH 639244 A5 CH639244 A5 CH 639244A5
- Authority
- CH
- Switzerland
- Prior art keywords
- coli
- food
- milk
- colim
- gental
- Prior art date
Links
- 235000013305 food Nutrition 0.000 title claims description 29
- 235000020256 human milk Nutrition 0.000 title claims description 3
- 210000004251 human milk Anatomy 0.000 title claims description 3
- 235000013336 milk Nutrition 0.000 title description 2
- 239000008267 milk Substances 0.000 title description 2
- 210000004080 milk Anatomy 0.000 title description 2
- 229960005486 vaccine Drugs 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 235000019687 Lamb Nutrition 0.000 claims description 8
- 235000007164 Oryza sativa Nutrition 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 8
- 235000009566 rice Nutrition 0.000 claims description 8
- 235000013372 meat Nutrition 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 5
- 235000020247 cow milk Nutrition 0.000 claims description 4
- 239000004006 olive oil Substances 0.000 claims description 4
- 235000008390 olive oil Nutrition 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 240000007594 Oryza sativa Species 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 description 33
- 241000588769 Proteus <enterobacteria> Species 0.000 description 9
- 206010025476 Malabsorption Diseases 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 230000037213 diet Effects 0.000 description 7
- 208000005577 Gastroenteritis Diseases 0.000 description 6
- 241000209094 Oryza Species 0.000 description 6
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 6
- 229960002739 oxaprozin Drugs 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 241000607142 Salmonella Species 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 235000010469 Glycine max Nutrition 0.000 description 4
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 241000588914 Enterobacter Species 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Natural products O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 3
- 208000012873 acute gastroenteritis Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 208000007442 rickets Diseases 0.000 description 3
- 201000004813 Bronchopneumonia Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 206010037213 Psychomotor retardation Diseases 0.000 description 2
- 208000031709 Skin Manifestations Diseases 0.000 description 2
- 235000020167 acidified milk Nutrition 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000013384 milk substitute Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- NNRXCKZMQLFUPL-WBMZRJHASA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2r,3 Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 NNRXCKZMQLFUPL-WBMZRJHASA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000004940 Bloch-Sulzberger syndrome Diseases 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010014198 Eczema infantile Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000007031 Incontinentia pigmenti Diseases 0.000 description 1
- 206010023648 Lactase deficiency Diseases 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 201000010859 Milk allergy Diseases 0.000 description 1
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 208000033787 Rare developmental defect during embryogenesis Diseases 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- FRYDSOYOHWGSMD-UHFFFAOYSA-N [C].O Chemical class [C].O FRYDSOYOHWGSMD-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 229940098166 bactrim Drugs 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 108010033929 calcium caseinate Proteins 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 201000008560 complement component 3 deficiency Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 235000021051 daily weight gain Nutrition 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 208000022734 developmental defect during embryogenesis Diseases 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229940098008 erythrocin Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- CEAZRRDELHUEMR-UHFFFAOYSA-N gentamicin Chemical compound O1C(C(C)NC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N CEAZRRDELHUEMR-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 description 1
- 208000035853 malformation syndrome Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940063639 rifadin Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960003292 rifamycin Drugs 0.000 description 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
- 235000021148 salty food Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 229940033504 soybean preparation Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000021076 total caloric intake Nutrition 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C11/00—Milk substitutes, e.g. coffee whitener compositions
- A23C11/02—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins
- A23C11/10—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing or not lactose but no other milk components as source of fats, carbohydrates or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
- A23L13/40—Meat products; Meat meal; Preparation or treatment thereof containing additives
- A23L13/42—Additives other than enzymes or microorganisms in meat products or meat meals
- A23L13/426—Addition of proteins, carbohydrates or fibrous material from vegetable origin other than sugars or sugar alcohols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Pediatric Medicine (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Dairy Products (AREA)
- Cereal-Derived Products (AREA)
Description
La presente invenzione concerne un alimento sostitutivo del latte materno e del latte vaccino contenente le sostanze nutritive indispensabili ad assicurare un accrescimento sano ed armonioso per bambini della prima e della seconda infanzia. The present invention relates to a substitute food for breast milk and cow's milk containing the nutrients essential for ensuring a healthy and harmonious growth for infants of first and second childhood.
Già nel 1929 Hill L. W. e Stuart H. C. [«A soy bean préparation for feeding infants with milk idiosyncrasy» J. A. M. A. 93 985, (1929)] avevano suggerito di alimentare i bambini affetti da intolleranza al latte vaccino con preparazioni liquide derivate dai semi di soia. As early as 1929 Hill L. W. and Stuart H. C. ["A soy bean preparation for feeding infants with milk idiosyncrasy" J. A. M. A. 93 985, (1929)] had suggested feeding children suffering from intolerance to cow's milk with liquid preparations derived from soybeans.
Precedenti esperimenti, come gli stessi Autori riportano, fatti con diete prive di latte somministrate a lattanti con eczema, avevano dato pessimi risultati, dato che i bambini miglioravano sì dalle manifestazioni cutanee, ma andavano incontro a disturbi digestivi gravi che finivano per essere molto più pericolosi dell'eczema stesso. Previous experiments, as the Authors themselves report, made with milk-free diets administered to infants with eczema, had given very bad results, given that the children improved yes from the skin manifestations, but they faced serious digestive disorders that ended up being much more dangerous of the eczema itself.
Preparazioni a base di latte di soia per l'alimentazione del bambino sono in commercio anche in Italia; tali preparazioni sono sia di provenienza estera che di fabbricazione italiana. Queste preparazioni di semi di soia non sempre sono tollerate bene da tutti i bambini affetti da disturbi di mal-assorbimento intestinale e non sono risolutive nella rialimentazione dopo gastroenterite, per cui in pratica, non sono divenute di uso corrente. L'esistenza poi di casi documentati (v. Mendoza J. et al. Pediatrica, Voi. 16, No. 5-1970) di intolleranza alla soia, fa sì che l'uso di questi alimenti può non essere seguito da successo. Soy milk preparations for feeding the baby are also on sale in Italy; these preparations are both of foreign origin and of Italian manufacture. These soybean preparations are not always well tolerated by all children suffering from intestinal malabsorption disorders and are not decisive in re-feeding after gastroenteritis, so in practice they have not become common use. The existence of documented cases (see Mendoza J. et al. Pediatrica, Vol. 16, No. 5-1970) of soy intolerance means that the use of these foods may not be followed by success.
Anche le preparazioni di caseinato di calcio e di latti acidificati chimicamente sono state — in anni recenti — abbandonate per l'emergenza di nozioni riguardanti l'allergia alle proteine del latte di cui questi prodotti sono costituiti e per il deficit secondario di lattasi che si instaura nel malas-sorbimento da qualsiasi causa determinato e che quindi non fa cessare la diarrea cronica dato che il lattosio è pur sempre contenuto, sia pure in dose ridotta, nei latti acidificati. Also the preparations of calcium caseinate and chemically acidified milks have been - in recent years - abandoned due to the emergence of notions concerning the allergy to milk proteins of which these products are made and to the secondary lactase deficiency that is established in malabsorption from any specific cause and which therefore does not stop chronic diarrhea since lactose is still contained, albeit in a reduced dose, in acidified milks.
È pertanto scopo della presente invenzione provvedere un alimento sostitutivo del latte in grado di costituire un sistema alimentare globale, predosato, sterile, adatto per la prima e per la seconda infanzia, pronto per l'uso e privo degli inconvenienti dei preparati alimentari noti. It is therefore an object of the present invention to provide a milk substitute food capable of constituting a global, pre-dosed, sterile food system, suitable for first and second childhood, ready for use and free from the drawbacks of known food preparations.
È altresì scopo della presente invenzione provvedere un alimento sostitutivo del latte per la prima e per la seconda infanzia particolarmente adatto ad essere somministrato nei seguenti casi: It is also an object of the present invention to provide a milk substitute food for first and second childhood particularly suitable for administration in the following cases:
— ripresa alimentare dopo episodi diarroici; - food recovery after diarrheal episodes;
— sindrome di malassorbimento intestinale da qualsiasi causa; - intestinal malabsorption syndrome from any cause;
— intolleranza alle proteine del latte vaccino e della carne bovina; - intolerance to cow's milk and beef proteins;
— intolleranza al lattosio e ad altri disaccaridi; - lactose intolerance and other disaccharides;
— intolleranza alla soia; - soy intolerance;
— manifestazioni allergiche cutanee (eczema infantile); - allergic skin manifestations (infantile eczema);
— manifestazioni allergiche respiratorie (asma bronchiale; - allergic respiratory manifestations (bronchial asthma;
5 stato di male asmatico; asma bronchiale intrattabile e così via); 5 state of asthmatic illness; intractable bronchial asthma and so on);
— anemia ferripriva; - iron anemia;
— scarso accrescimento staturale; - poor growth in statistics;
— anoressia; - anorexia;
io — soggetti normali specialmente in situazioni di emergenza quali viaggi, soggiorni fuori dell'ambiente abituale con problemi di approvvigionamento degli ingredienti alimentari e così via. I - normal subjects especially in emergency situations such as travel, stays outside the usual environment with problems of supply of food ingredients and so on.
Questi ed altri scopi sono raggiunti con l'alimento se-15 condo l'invenzione, contenente carne di agnello 150 - 200 g crema di riso 150 - 200 g olio di oliva 10 - 30 g sale fino (NaCl) 0,5 - 2 g 20 acqua q.b. a l'OOO mi. These and other purposes are achieved with the food according to the invention, containing lamb meat 150 - 200 g rice cream 150 - 200 g olive oil 10 - 30 g fine salt (NaCl) 0.5 - 2 g 20 water to taste a l'OOO mi.
La carne di agnello deve essere magra, privata di fasce, tendini, connettivo e ridotta ad una purea omogenea mediante passaggio all'omogeneizzatore; la crema di riso non 25 deve avere additivi e deve essere cotta per venti minuti; quindi si uniscono l'omogeneizzato di carne di agnello e la crema di riso cotta, si aggiunge il sale e l'olio, si porta a volume di 1 litro con acqua sterile e si distribuisce in contenitori di vetro da 100 mi. Il vetro, naturalmente, deve essere di com-30 posizione tale da non cedere elementi pericolosi. La chiusura ermetica è del tipo noto. Lamb meat must be lean, without bands, tendons, connective tissue and reduced to a homogeneous puree by passing it to the homogenizer; rice cream 25 must not have additives and must be cooked for twenty minutes; then the homogenised lamb meat and the cooked rice cream are added, the salt and oil are added, it is brought to a volume of 1 liter with sterile water and is distributed in 100 ml glass containers. Naturally, the glass must be of such a position that it does not release dangerous elements. The hermetic seal is of the known type.
Potrebbe essere aggiunto calcio fosfato colloidale nella dose di 20 mg ogni 100 mi di alimento cioè 200 mg in 1000 mi, per cui si assicurerebbe un apporto giornaliero di 35 120-200 mg al giorno di calcio e di fosforo, come raccomandato. Comunque quest'aggiunta non è indispensabile; al bambino vanno somministrate le vitamine come d'abitudine, sotto forma di miscele a gocce quali Protovit®(1>, Abi-dec®((2), Idroplurivit®(3), e così via. Si potrebbero aggiun-40 gere uno o due cucchiaini giornaleri di un prodotto a base di fosfato di calcio (per esempio Ca-Steorgyl®(4); Calci-oste-lin B12®(5) e così via) preferibilmente che non contengano lattosio. Colloidal calcium phosphate could be added in a dose of 20 mg per 100 ml of food, that is, 200 mg in 1000 ml, so it would ensure a daily intake of 35 120-200 mg per day of calcium and phosphorus, as recommended. However this addition is not essential; vitamins should be administered to the child as usual, in the form of drop mixtures such as Protovit® (1>, Abi-dec® ((2), Idroplurivit® (3), and so on). or two daily spoons of a calcium phosphate-based product (for example Ca-Steorgyl® (4); Calci-oste-lin B12® (5) and so on) preferably which do not contain lactose.
Per bambini particolarmente abituati al sapore dolce del-45 le pappe di latte e che pertanto potrebbero rifiutare l'alimento salato oggetto della presente invenzione, si possono sostituire da 20 a 30 g di crema di riso con glucosio sotto forma, per esempio di Dextropur®(6). For children particularly accustomed to the sweet taste of 45 baby food and who therefore could refuse the salty food object of the present invention, 20 to 30 g of rice cream can be replaced with glucose in the form, for example of Dextropur® (6).
Nella sua forma di realizzazione preferita l'alimento del-50 la presente invenzione contiene: In its preferred embodiment the food of the present invention contains:
carne di agnello 180 g crema di riso 180 g olio di oliva 15 g lamb meat 180 g rice cream 180 g olive oil 15 g
55 sale fino (NaCl) 1 g acqua q.b. a l'OOO mi. 55 fine salt (NaCl) 1 g water to taste a l'OOO mi.
L'alimento della presente invenzione ha una composizione pari a: carboidrati 72%; proiteine 14,4%; grassi 60 13,5%. The food of the present invention has a composition equal to: 72% carbohydrates; proiteine 14.4%; fats 60 13.5%.
<!> Hoffmann La Roche, Basel (Ch). <!> Hoffmann La Roche, Basel (Ch).
<2> Parke Davis, Detroit (U.S.A.). <2> Parke Davis, Detroit (U.S.A.).
65 (S) Menarini A. S.a.S., Firenze. 65 (S) Menarini A. S.a.S., Florence.
<4> Roussel Maestretti, S.p.A., Mileno. <4> Roussel Maestretti, S.p.A., Mileno.
<5ì Glaxo Laboratories Ltd., Greenford (Gran Bretagna). <5ì Glaxo Laboratories Ltd., Greenford (Great Britain).
<6> Monda, S.p.A., Milano. <6> Monda, S.p.A., Milan.
3 3
639244 639244
Poiché 18 g di crema di riso forniscono 72 calorie, 18 g di carne di agnello magra circa 15 calorie ed 1,5 g di olio circa 13 calorie si ha che 100 mi di alimento forniscono 100 calorie. Questa identità fra volume e calorie permette di facilitare e semplificare l'impostazione della razione alimentare nel bambino piccolo. Per ogni kg di peso corporeo del bambino si danno come razione minima 100 calorie giornaliere che corrispondono a 100 mi di alimento. Per fare questo è sufficiente conoscere il peso del bambino in grammi e dargli il quantitativo di alimento corrispondente alle prime tre cifre arrotondate a quelle tonde immediatamente superiori; questo quantitativo di omogeneizzato va diluito con una metà del volume globale di acqua. Per esempio ad un bambino d!i kg 5,700 si dovrebbero dare 570 mi di alimento della presente invenzione che, in pratica, si può arrotondare a 600 mi, cui vanno aggiunti 300 mi di acqua (cioè 600:2). Per singolo pasto, se il bambino è a 6 pasti, riceverà 100 mi di alimento della presente invenzione diluito con 50 mi di acqua e cioè sei pasti da 150 mi; se invece il bambino è a 5 pasti riceverà 120 mi di alimento dalla presente invenzione cui andranno aggiunti 60 mi di acqua, cioè un totale di 180 mi. Since 18 g of rice cream provides 72 calories, 18 g of lean lamb about 15 calories and 1.5 g of oil about 13 calories, 100 ml of food provide 100 calories. This identity between volume and calories allows to facilitate and simplify the setting of the food ration in the young child. For each kg of the child's body weight, a minimum ration of 100 daily calories is given, which corresponds to 100 ml of food. To do this, it is sufficient to know the weight of the child in grams and give him the quantity of food corresponding to the first three figures rounded to the immediately higher round ones; this quantity of homogenate must be diluted with half the overall volume of water. For example, a child of 5,700 kg should be given 570 ml of food of the present invention which, in practice, can be rounded to 600 ml, to which 300 ml of water (i.e. 600: 2) must be added. For a single meal, if the child is at 6 meals, he will receive 100 ml of food of the present invention diluted with 50 ml of water, that is, six 150 ml meals; if instead the child is at 5 meals he will receive 120 ml of food from the present invention to which 60 ml of water will be added, that is a total of 180 ml.
Se il bambino non si dovesse saziare, o dovesse aumentare poco di peso (meno di 25-30 g al giorno, a seconda dell'età) si dovrà aumentare l'apporto calorico totale a 110 o anche a 120 calorie per kg al giorno. Per ottenere i grammi di alimento da dare basterà moltiplicare le prime tre cifre del peso in grammi per 1,1 e si avranno i quantitativi pari a 120 cal/kg/die. Per assicurare il fabbisogno idrico bisogna aggiungere 150-160 ml/kg/die. Può essere valida la quantità già suggerita ossia una quantità di acqua espressa in mi pari alla metà del volume di alimento della presente invenzione. Per ogni kg di peso corporeo del bambino si danno con l'alimento della presente invenzione 3,6 g di proteine, 1,5 g di grassi e 18 g di idrati di carbonio, e procedendo all'aggiunta della metà del volume di acqua 150 mi di acqua stessa. If the child does not become satiated, or should gain little weight (less than 25-30 g per day, depending on age), the total calorie intake must be increased to 110 or even 120 calories per kg per day. To obtain the grams of food to be given, just multiply the first three digits of the weight in grams by 1.1 and you will have the quantities equal to 120 cal / kg / day. To ensure the water requirement, 150-160 ml / kg / day must be added. The amount already suggested can be valid, i.e. an amount of water expressed in ml equal to half the volume of food of the present invention. For each kg of body weight of the child, 3.6 g of protein, 1.5 g of fat and 18 g of carbon hydrates are given with the food of the present invention and adding half the volume of water 150 I of water itself.
L'alimento della presente invenzione è stato dato anche con successo a bambini di peso molto basso e cioè di 2,5 kg. The food of the present invention has also been successfully given to children of very low weight, i.e. 2.5 kg.
Alimentando i bambini con l'alimento della presente invenzione si assiste alla comparsa di un ottimo appetito, all'emissione di 0-3 scariche al dì, formate, alcaline, di colore bruniccio. Inoltre, i bambini così trattati, sono anche di buon umore, non hanno dolori addominali, dimostrano una maggior energia nelle risposte motorie e della vita di relazione ed hanno un accrescimento ponderale e staturale normale, o addirittura accelerato. Anche la loro sanguinifica- By feeding children with the food of the present invention, there is an excellent appetite, the emission of 0-3 discharges per day, formed, alkaline, brownish in color. In addition, the children treated in this way are also in a good mood, do not have abdominal pain, show greater energy in motor and relationship life responses and have normal or even accelerated weight and stat growth. Even their bleeding-
zione migliora in maniera sorprendente, forse perché ricevono una grande quantità di ferro legato alle proteine della carne di agnello. tion improves in a surprising way, perhaps because they receive a large amount of iron bound to the proteins of lamb.
L'alimento della presente invenzione si è dimostrato par-5 ticolarmente utile nei casi di gastroenterite acuta, di sindrome di malassorbimento, infezioni broncopolmonari, rachitismo, ritardo psicomotorio. The food of the present invention has proven to be particularly useful in cases of acute gastroenteritis, malabsorption syndrome, bronchopulmonary infections, rickets, psychomotor retardation.
33 bambini di età compresa fra 1 e 24 mesi alcuni dei quali sono stati ricoverati più volte per diverse cause, per io un totale di 41 degenze, sono stati trattati con una dieta contenente l'alimento della presente invenzione. 33 children aged between 1 and 24 months, some of whom were hospitalized several times for various causes, for me a total of 41 hospital stays, were treated with a diet containing the food of the present invention.
Queste degenze sono state originate in 23 casi da gastroenterite acuta, in 9 da sindrome di malassorbimento ed in 9 da patologia varia (infezioni broncopolmonari, rachitismo, 15 ritardo psicomotorio, vedi tabella allegata). These hospitalizations originated in 23 cases from acute gastroenteritis, in 9 from malabsorption syndrome and in 9 from various pathologies (bronchopulmonary infections, rickets, 15 psychomotor retardation, see attached table).
La dieta contenente l'alimento della presente invenzione è stata usata sia come trattamento dietetico in fase di rialimentazione nei soggetti affetti da gastroenterite acuta con grave perdita di peso, sia come dieta di base per l'alimenta-20 zione dei bambini affetti da sindrome di malassorbimento intestinale o da altri stati morbosi. The diet containing the food of the present invention has been used both as a dietary treatment during re-feeding in subjects suffering from acute gastroenteritis with severe weight loss, and as a basic diet for the feeding of children suffering from intestinal malabsorption or other morbid conditions.
Per valutare l'efficacia di questa dieta si sono presi in considerazione i seguenti parametri: To evaluate the effectiveness of this diet, the following parameters were taken into consideration:
25 1) tempo di normalizzazione dell'alvo in soggetti con diarrea; 25 1) normalization time of the alve in subjects with diarrhea;
2) incremento giornaliero in peso. 2) daily increase in weight.
II tempo di normalizzazione dell'alvo è stato vario, oscillando da un minimo di 24 ore ad un massimo di 12 giorni 30 con un valore medio per soggetto di 2,5 giorni, pari a 60 ore. È da notare che in 9 soggetti (32% dei casi) l'alvo si è regolarizzato entro 24 ore ed in 17 soggetti (60%) in 48 ore; in un solo caso, tale terapia dietetica non sembra aver sortito alcun effetto immediato poiché la normalizzazione 35 dell'alvo si ebbe solo dopo 12 giorni, ma trattandosi di una piccola paziente affetta da grave sindrome malformativa quale la «Incontinentia pigmenti», non ci sembra che tale caso sia paradigmatico per valutare l'effetto di tale dieta. The normalization time of the alvo was varied, ranging from a minimum of 24 hours to a maximum of 12 30 days with an average value per subject of 2.5 days, equal to 60 hours. It should be noted that in 9 subjects (32% of cases) the alve regularized within 24 hours and in 17 subjects (60%) in 48 hours; in one case, this diet therapy does not seem to have had any immediate effect since the normalization 35 of the alvo occurred only after 12 days, but since it is a small patient suffering from a serious malformation syndrome such as "Incontinentia pigmenti", it does not seem that this case is paradigmatic to evaluate the effect of this diet.
Anche per l'incremento giornaliero di peso i dati sono 40 stati vari oscillando da un minimo di 10 g ad un massimo di 100 g con un valore medio di 40 g al giorno per soggetto. Also for the daily weight gain, the data were 40 various states ranging from a minimum of 10 g to a maximum of 100 g with an average value of 40 g per day per subject.
Il valore medio di incremento ponderale giornaliero è risultato: The average daily weight increase was:
45 per soggetti affetti da gastroenterite: 42 g al giorno; 45 for people with gastroenteritis: 42 g per day;
per soggetti affetti da malassorbimento: 40 g al giorno; for subjects with malabsorption: 40 g per day;
per soggetti affetti da altra patologia: 40 g al giorno. for subjects suffering from other pathology: 40 g per day.
Bambino N. Child N.
ETÀ' mesi AGE months
DIAGNOSI DIAGNOSIS
FEBRE per giorni FEBRE for days
COPROCOLT. COPROCOLT.
NORMAL, alvo in gg. NORMAL, alvo in days
ANTIBIOT. Antibiot.
Prima Kg. First Kg.
P E S P E S
^ ' ^ '
•d • d
U, U,
<L> <L>
a. to.
O OR
Uscita Kg. Output Kg.
Incr./die gr- Incr./die gr-
1 1
13 13
G.E. M. G.E. M.
6 6
E. Coli E. Coli
Salmonella Salmonella
3 3
Gental. Colim. Gental. Colim.
7,0 7.0
9,2 9.2
7,1 7.1
44 44
2 2
8 8
G.E. B. G.E. B.
11 11
E. Coli Salmonella E. Coli Salmonella
- -
Gentai. Colim. Gentai. Colim.
00 co 00 co
3,0 3.0
co co co co
20 20
3 3
9 9
G.E. G.E.
3 3
E. Coli Proteus E. Coli Proteus
3 3
Gental. Colim. Gental. Colim.
6,9 6.9
7,2 7.2
6,7 6.7
100 100
* *
ON ON
UT UT
u> u>
ro ro
- -
o or
00 00
<1 <1
GN GN
Ul Ul
Bambino N. Child N.
—i -the
-P> -P>
i o I
CO CO
ro ro
V V
CO CO
i the
1 1
co co
ON ON
O OR
ro ro
ì the
CO CO
ETÀ' mesi AGE months
a to
O OR
M M
Q M Q M
s s
O M O M
s w s w
M M
G.E. C. G.E. C.
Q t?a Q t? A
G.E. G.E.
o or
D3 D3
G.E. j G.E. j
DIAGNOSI DIAGNOSIS
no no no no
Co Co
IO I
no no
U1 U1
no ro no ro
! !
ou ou
Co no no Co no no
CO CO
- -
FEBRE per giorni FEBRE for days
E- Coli i E- Coli i
E. Coli Salmonella E. Coli Salmonella
E. Coli E. Coli
E. Coli Entero-bact; E. Coli Entero-bact;
'E. Coli ■S almo-nella 'IS. Coli ■ S almo-nella
E. Coli Proteus mirab. E. Coli Proteus mirab.
E. Coli neg. E. Coli neg.
E. Coli S almo-nella E. Coli S almo-nella
E. Coli E. Coli
E. Coli Proteus mirabilis E. Coli Proteus mirabilis
E. Coli E. Coli
E. Coli E. Coli
COPROCOLT. COPROCOLT.
_A _TO
i the
-p=. -p =.
IO I
i the
4* 4 *
1 1
I THE
1 1
ro ro ro ro
CO CO
- -
- -
NORMAL, alvo _jn gg- NORMAL, alvo _jn gg-
1 1
Ampi. Eritr. Large. Eritr.
■ ■
' '
i the
Gental Gental
I THE
1 1
Colim. Gental Colim. Gental
Colim. Gental Colim. Gental
Colim. Colim.
Gental. Colim. Amplit. Gental. Colim. Amplit.
Gental. Colim. Gental. Colim.
ANTIBIOT. Antibiot.
VO CO VO CO
CO CO
VJ1 VJ1
fO SC
KJÌ KJI
l£> l £>
i the
•vj CO • vj CO
CO CO
ro ro
\ \
o or
CO CO
ON O OR NOT
*-0 «• * -0 «•
CN CO CN CO
CO CO
i the
CO CO
L'OL The OL
Prima Kg. First Kg.
1 1
1 1
1 1
i i i i
s'i? Yes?
1 1
! !
1 1
ro ro
U1 U1
—A -TO
4,2 4.2
I THE
4,9 4.9
TJ TJ
Perd. % tu For D. % you
CÖ Ço
vo vo
VJ1 VJ1
CO CO
' -0 '-0
VJ1 VJ1
on on
3,7 3.7
KD CO KD CO
IO I
00 • yi 00 • yi
* *
i ro i ro
ON ON
•<i • <i
ON ON
CO CO
00 00
11,5 11.5
—A -TO
o o o o
CJ CJ
Uscita Kg. Output Kg.
O OR
ON O OR NOT
io o I or
CO CO
co ro co ro
U1 U1
IO Ul I Ul
ON O OR NOT
\o o i \ o or i
U1 VJl U1 VJl
100 100
100 100
U1 U1
o o o o
Incr./die gr. Incr./die gr.
On SO On SO
E IS
to to
CO CO
o or
IO KD I KD
ro co ro co
IO I
ro ro
ON ON
IO Ul I Ul
IO I
4^ 4 ^
IO Co IO Co
IO IO I am
IO I
IO O I OR
KD KD
co co
Bambino N. Child N.
J J
ON ON
4^ 4 ^
IO 4* IO 4 *
- -
Ul Ul
4^ 4 ^
ON ON
to to
IO I
_1 _1
co co
O OR
IO I
Ul co Ul co
ETÀ' mesi AGE months
£D £ D
m m
G.E. G.E.
G.E. I.P. G.E. Permanent Disability
o or
M M
I.V.U. I.V.U.
Q Cd Q Cd
O M O M
Q M Q M
M. M.
I.V.U. I.V.U.
sa know
O OR
Q H Q H
G.E. G.E.
Bt. Bt.
a m to m
C.L. C.L.
DIAGNOSI DIAGNOSIS
Ì THE
IO I
- -
Co Co
1 1
CO CO
ES O ES O
Ul Ul
C3 O C3 O
Ö OR
o i or i
s o s o s or s o
FEBRE per giorni FEBRE for days
Proteus E. Coli Proteus E. Coli
E. Coli Citrobacter. E. Coli Citrobacter.
E. Coli Proteus E. Coli Proteus
E. Coli Proteus E. Coli Proteus
E. Coli E. Coli
Klebs. Klebs.
Enterob. Enterob.
E. Coli Proteus Klebs. E. Coli Proteus Klebs.
E. Coli Proteus Citrob. E. Coli Proteus Citrob.
1 1
E. Coli Proteus E. Coli Proteus
E. Coli ; E. Coli;
E. Coli Enterobacter. E. Coli Enterobacter.
E. Coli Enterobacter. E. Coli Enterobacter.
E. Coli Klebs. E. Coli Klebs.
E. Coli Enterob. E. Coli Enterob.
i the
COPROCOLT. COPROCOLT.
CO CO
-» - »
IO I
- -
i the
IO I
-f* -f *
O OR
CO CO
IO I
- -
GN GN
i the
NORMAL, alvo in gg. NORMAL, alvo in days
Colim. Colim.
i the
Colim. Gental. Colim. Gental.
Colim. Colim.
Gental. Bactrim Humatin Gental. Bactrim Humatin
1 1
SJ Q h- m ir> Ö r+ ÇL £U H SJ Q h- m ir> Ö r + ÇL £ U H
Colim. Gental Colim. Gental
Kanam. Kanam.
i the
Ampi. Eri tr. Large. You were tr.
i i i i
ANTIBIOT. Antibiot.
9,5 9.5
■<! ■ <!
O'L O'L
4,7 4.7
co co
CO KD CO KD
4,7 4.7
« "
4,6 4.6
*•«0 * • "0
KD KD
7,4 7.4
i the
VI YOU
V V
Prima Kg. First Kg.
i the
1 1
i the
1 1
1 1
1 1
1 1
1 1
J J
1 1
1 1
! !
i l i l
n n
Perd. °7o fu c/3 For D. ° 7o was c / 3
o or
9,8 9.8
7,0 7.0
7,9 7.9
Ul Ul
1 1
ON ON
Ul Ul
Co Co
Ul Ul
Ul Ul
. io . I
9,3 9.3
<3 % <3%
co o co o
VD VD
i the
Ul o\ Ul or \
Uscita Kg. Output Kg.
ON ON
io I
Ul ON Ul ON
IO KD I KD
Ul o Ul o
4^ 4 ^
ro ro
ON ON
4* 4 *
IO I
IO I
1 1
Ul Ul
IO Ul I Ul
Ul Ul Ul Ul
Incr./die gr- Incr./die gr-
Ul Ul
Os w ve Os w ve
K K
639244 6 639244 6
Bambino N. Child N.
ETÀ' mesi AGE months
DIÀGNOSI DIAGNOSIS
FEBRE per giorni FEBRE for days
COPROCOLT. COPROCOLT.
NORMAL, alvo in gg. NORMAL, alvo in days
ANTIBIOT. Antibiot.
Prima Kg. First Kg.
PESI -a u< WEIGHTS -a u <
il the
CU CU
I-I I-I
Uscita Kg. Output Kg.
Incr./die gr. Incr./die gr.
32 32
22 22
G.E. G.E.
1 1
Salmonella Salmonella
2 2
Colim. Gental. Colim. Gental.
10,7 10.7
- -
11 ,0 11, 0
30 30
33 33
6 6
G.E. G.E.
no no
E. Coli E. Coli
Enterob. Enterob.
Cloacae cloacae
3 3
- -
7,0 7.0
- -
7,1 7.1
20 20
34 34
9 9
M. M.
2 2
E. Coli E. Coli
Enterob. Enterob.
Cloacae cloacae
2 2
- -
6,8 6.8
- -
7,1 7.1
60 60
35 35
4 4
S.A.L.V. S.A.L.V.
no no
E. Coli Enterobacter E. Coli Enterobacter
1 1
- -
8,8 8.8
- -
8,9 8.9
30 30
36 36
2 2
S.A.L.V. M. S.A.L.V. M.
no no
E. Coli E. Coli
Enterob, Enterob,
Cloacae cloacae
- -
- -
4,2 4.2
- -
4,3 4.3
33 33
37 37
20 20
M. M.
no no
E. Coli E. Coli
- -
- -
13,6 13.6
- -
13,8 13.8
22 22
38 38
11 11
M. M.
4 4
E. Coli Salmonella E. Coli Salmonella
2 2
Ampi. Large.
9,7 9.7
- -
9,9 9.9
15 15
39 39
13 13
E.P.M. E.P.M.
3 3
- -
- -
Ampi. Gental. Large. Gental.
7,8 7.8
- -
8,0 8.0
33 33
40 40
9 9
M. M.
- -
E. Coli Proteus Mirab. E. Coli Proteus Mirab.
1 1
- -
8,1 8.1
- -
8,3 8.3
80 80
41 41
15 15
M. M.
- -
E. Coli Pseudomonas E. Coli Pseudomonas
- -
- -
9,8 9.8
- -
10,0 10.0
25 25
Diagnosi: G. E. = gastro enterite; M. = malassorbimento intestinale; B. = bronchite; C. = convulsioni; Diagnosis: G. E. = gastro enteritis; M. = intestinal malabsorption; B. = bronchitis; C. = convulsions;
R. P. M. = ritardo psico-motorio; I.P. = in- Antibiotici: R. P. M. = psycho-motor delay; Permanent Disability = in- Antibiotics:
continentia pigmenti e deficit di C3; 55 C. L. = crosta lattea; Bt. = bronchiolite; continentia pigmenti and C3 deficiency; 55 C. L. = milky crust; Bt. = Bronchiolitis;
Re = rachitismo; I.V.U. = infezione vie urinarie; Re = rickets; I.V.U. = urinary tract infection;
S. A. L. V. = sospetta allergia alle proteine del latte vaccino. S. A. L. V. = suspected allergy to cow's milk proteins.
Colim. = Colimicina; Gental. = Gentalyn (Gentamicina); Ampi. = Amplital (Ampicilline); Rifad. = Rifadin (Rifamicina); Eritr. = Eritrocina (Eritromicino); Kanam. = Kanami-cina. Colim. = Colimicine; Gental. = Gentalyn (Gentamicina); Large. = Amplital (Ampicilline); Rifad. = Rifadin (Rifamycin); Eritr. = Erythrocin (Erythromycin); Kanam. = Kanami-china.
v v
Claims (2)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT22170/78A IT1095385B (en) | 1978-04-10 | 1978-04-10 | SUBSTITUTE FOOD FOR MOTHER'S MILK AND VACCINE MILK |
Publications (1)
Publication Number | Publication Date |
---|---|
CH639244A5 true CH639244A5 (en) | 1983-11-15 |
Family
ID=11192533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH332079A CH639244A5 (en) | 1978-04-10 | 1979-04-09 | SUBSTITUTE FOOD FOR BREAST MILK AND VACCINE MILK. |
Country Status (5)
Country | Link |
---|---|
CH (1) | CH639244A5 (en) |
DE (1) | DE2914344A1 (en) |
FR (1) | FR2422340A1 (en) |
GB (1) | GB2018120B (en) |
IT (1) | IT1095385B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2225206A (en) * | 1988-11-01 | 1990-05-30 | William Maddern | "Vit-lap" - a protein drink for pets |
FR2825003B1 (en) * | 2001-05-28 | 2005-01-28 | Taan Aboudiab | DEVICE FOR DIETETIC FOOD FOR SUBSTITUTION OF MILK AND SOYBEANS |
DE102005060945A1 (en) * | 2005-12-20 | 2007-06-21 | Ingeborg Laufer | Preparation of food, useful to prevent or decrease lactose intolerance, which are made of lactose free milk, milk-derivatives and/or milk products on vegetable base and meat or a meat product |
-
1978
- 1978-04-10 IT IT22170/78A patent/IT1095385B/en active
-
1979
- 1979-04-09 GB GB7912350A patent/GB2018120B/en not_active Expired
- 1979-04-09 CH CH332079A patent/CH639244A5/en not_active IP Right Cessation
- 1979-04-09 DE DE19792914344 patent/DE2914344A1/en not_active Withdrawn
- 1979-04-09 FR FR7908921A patent/FR2422340A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
IT7822170A0 (en) | 1978-04-10 |
IT1095385B (en) | 1985-08-10 |
GB2018120B (en) | 1985-06-12 |
FR2422340A1 (en) | 1979-11-09 |
DE2914344A1 (en) | 1979-10-18 |
GB2018120A (en) | 1979-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Davoodi et al. | Health-related aspects of milk proteins | |
Nagpal et al. | Milk, milk products, and disease free health: an updated overview | |
AU709155B2 (en) | Compositions and methods for human gastrointestinal health | |
JP6285108B2 (en) | Probiotics in pre-operative and / or post-operative environments | |
RU2482705C2 (en) | High-energy liquid enteral nutritional composition | |
JP2004506437A (en) | Nutritional compositions and methods for improving protein accumulation | |
ES2314485T3 (en) | COMPOSITIONS THAT INCLUDE PANTOTENIC ACID OR DERIVATIVES OF THE SAME AND ITS USE TO STIMULATE THE APPETITE. | |
CN101370491A (en) | Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition | |
CN103458890A (en) | Nutritional compositions including branched chain fatty acids and methods of using same | |
US10751362B2 (en) | Compositions and methods for managing digestive disorders and a healthy microbiome | |
JP2004521141A (en) | High calorie fluid oral supplement | |
US20170182132A1 (en) | Use of nutritional compositions including lactoferrin in supporting resistance to diseases and conditions | |
CN105942506A (en) | Special medical application formula food suitable for patients suffering from liver diseases | |
JP5335601B2 (en) | Nutritional composition | |
Ribeiro et al. | Oral iron supplementation in patients with chronic kidney disease: Can it be harmful to the gut microbiota? | |
CN105614860A (en) | Probiotic compound oligopeptide nutritional supplement capable of lowering uric acid | |
Shepherd | Nutrition through the life span. Part 3: adults aged 65 years and over | |
CN107467193B (en) | A powder food based on goat milk for special medical use and its preparation method | |
Liutkevičius et al. | Development of a functional whey beverage, containing calcium, vitamin D, and prebiotic dietary fiber, and its influence on human health | |
CH639244A5 (en) | SUBSTITUTE FOOD FOR BREAST MILK AND VACCINE MILK. | |
EP1638418A1 (en) | Amino acid supplementation for a healthy microbiota ecosystem | |
JP6037595B2 (en) | Satiety induction composition and method for producing the same | |
JPS5832867B2 (en) | Eggs containing high concentrations of lysozyme and iodine | |
US20120171163A1 (en) | Method for inhibiting a bacterial invasive mechanism using a nutritional composition | |
Gogus | A fundamental guide for a healthy lifestyle and nutrition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PL | Patent ceased |